Lilly, UHG become research bedfellows
Eli Lilly and UnitedHealth Group announced early last month that they are teaming up to conduct a “pragmatic” study of Lilly’s bamlanivimab, a monoclonal antibody developed as a treatment for COVID-19.
Eli Lilly and UnitedHealth Group announced early last month that they are teaming up to conduct a “pragmatic” study of Lilly’s bamlanivimab, a monoclonal antibody developed as a treatment for COVID-19. The FDA’s emergency use authorization of bamlanivimab limits it use to patients who have not been hospitalized.
UnitedHealthcare Medicare Advantage members will be invited to participate. Study volunteers will use a symptom-checker app developed by Optum, which is part of UnitedHealth. If they experience symptoms, they will take a self-
administered test for SARS-Cov-2, the virus that causes COVID-19. An Optum Infusion Pharmacy nurse will oversee at-home infusions of bamlanivimab. Many non-COVID-19 patients getting treated at infusion centers are immunocompromised, so home infusion of this treatment might very well have some safety advantages. The primary outcome measure is hospitalizations in the 28-day period after the drug is infused.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
